April 7, 2014 Arno Therapeutics Enrolls First Patient in a Phase I/II Trial Evaluating Onapristone in Men with Advanced Castration-Resistant Prostate Cancer
April 2, 2014 Kite Pharma Announces the Appointment of Arie Belldegrun, M.D., as President and Chief Executive Officer
April 1, 2014 Arno Therapeutics Reports 2013 Financial Results and Provides Update on Strategic and Operational Milestones
March 31, 2014 Kite Pharma Announces FDA Orphan Drug Designation for Anti-CD19 T Cell Cancer Immunotherapy Product
March 28, 2014 Capricor Therapeutics to Present ALLSTAR Phase I Trial Data at ACC Annual Meeting 2014
March 26, 2014 Arno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014
March 4, 2014 Arno Therapeutics Granted Exclusive License for Oncology Diagnostic Technique by University of Minnesota
January 21, 2014 Arno Therapeutics Enrolls First Patient in a Phase I Trial to Evaluate Lead Compound Onapristone in Progesterone Receptor Positive Solid Tumors
January 17, 2014 Kite Pharma Appoints Rizwana F. Sproule, Ph.D., as Vice President, Regulatory Affairs
January 9, 2014 NeoStem’s Subsidiary, Progenitor Cell Therapy (PCT), to Provide Process Development and Manufacturing Services to Kite Pharma
January 7, 2014 Arno Therapeutics Selects Leica Biosystems to Develop Companion Diagnostic for Targeted Oncology Therapy Onapristone
January 6, 2014 Capricor Therapeutics and Janssen Biotech, Inc. Enter Into Collaboration Agreement and Exclusive License Option
December 17, 2013 Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack
December 14, 2013 Arno Therapeutics to Present Data on Two Potential Predictive Biomarkers at the San Antonio Breast Cancer Symposium 2013
December 7, 2013 New studies demonstrate that modified T cells are effective in treating blood-borne cancers
December 7, 2013 Kite Pharma’s Lead Program with the National Cancer Institute (NCI) Demonstrates Positive Results in Patients with Aggressive Non-Hodgkin’s Lymphoma
